- Challenges of antiangiogenic cancer therapy: trials and errors, and renewed hope
- CASE 2. Response in a Patient With Metastatic Adrenal Cortical Carcinoma With Thalidomide
- Fighting Cancer with Aspirin
- Anti-Angiogenic Protocol
- Copper May Play Role In 'Starving' Cancer To Standstill
- Copper deficiency as an anti-cancer strategy
- Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer—Part 1
- Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer—Part 2
- How Angiogenesis Inhibition Improves Chemotherapy Outcomes: An Expert Interview With Dr. Lee Ellis
- New Anti-angiogenesis Treatment: Combination Therapy Obliterates New Vessel Growth In Tumors And Retinopathy
- Angioprevention’: angiogenesis is a common and key target for cancer chemopreventive agents
- A Multitargeted, Metronomic, and Maximum-Tolerated Dose "Chemo-Switch" Regimen is Antiangiogenic, Producing Objective
Responses and Survival Benefit in a Mouse Model of Cancer - Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis.
- Fibrous capsule formation around titanium and copper.
- Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
- Low-dose Metronomic Combined with Intermittent Bolus-dose Cyclophosphamide Is an Effective Long-term Chemotherapy Treatment Strategy
- Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic
- Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics